Finanzas de Latigo Biotherapeutics, Inc. Common Stock (LTGO)LTGOLatigo Biotherapeutics, Inc. Common Stock

In the context of the broader market, LTGO competes directly with industry leaders such as MLTX and MNKD. With a market capitalization of $1.05B, it holds a significant position in the sector. When comparing efficiency, LTGO's gross margin of N/A stands against MLTX's N/A and MNKD's 69.00%. Such benchmarking helps identify whether Latigo Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Latigo Biotherapeutics has reported negative earnings consistently, with a net income of -25,797,000 USD in Q2 2026. The current ratio is 1.15, indicating adequate short-term liquidity, but the debt to equity ratio is concerning at 239.14%.